HEALIO: FDA: Avoid using smartwatches, smart rings to measure blood glucose
MEDSCAPE: New Hyperglycemia Emergency Guidance Updates DKA Definition
HEALIO: VIDEO: Areas of unmet need relating to diabetes technology
HEALIO: Use of CGM metrics more common in diabetes care, but still limited
HEALIO: VIDEO: New metric from CGM data provides single score for glucose assessment
MEDSCAPE: What Is the Glycemic Risk Index and Why Do We Need It?
UPI: Pacemakers, insulin pumps can be hacked, experts say
HEALIO: Glycemia Risk Index provides new tool for assessing glycemic control with CGM data
HEALIO: Stakeholders challenged to take action at first Green Diabetes Summit
MEDSCAPE: Continuous Ketone Monitoring Has Potential to Cut DKA in Diabetes
DIATRIBE: Glycemia Risk Index – An Emerging Measurement to Complement Your TIR
HEALIO: Connectivity, digital tools becoming the ‘sixth vital sign’ in health care
MEDSCAPE: Wearable Continuous Ketone Monitoring Appears Feasible
HEALIO: Continuous ketone monitoring may provide early identification of DKA
HP ENTERPRISE.NXT: How the edge is reshaping healthcare
MEDSCAPE: Protecting Patients With Diabetes From Impact of COVID-19
ENDOCRINOLOGY ADVISOR: Benefits of Continuous Glucose Monitoring Systems in the Hospital Setting
HEALIO: Telehealth shift during COVID-19 pandemic shows capacity to deliver safe, convenient care
ENDOCRINE NEWS: New App Helps Improve Diabetes Care in Patients with COVID-19
ENDOCRINE NEWS: Pandemic Parallels: Glycemic Control in COVID-19 Patients
MEDSCAPE: Largest Study to Date Links Glucose Control to COVID-19 Outcomes
NEWSDAY: Coronavirus poses special risks for diabetics
HEALIO: Uncontrolled hyperglycemia, diabetes drive longer hospital stay, mortality in COVID-19
ELSEVIER: Diabetes Digital Health (Edited by David Klonoff et al.)
HEALIO: Postoperative infections less frequent with insulin pump therapy for adults with diabetes
THE DIPLOMAT: Cost of Diabetes Reaches $850 Billion a Year Globally
May 23, 2017—Given today's increasingly challenging cybersecurity requirements, we are pleased to announce that Ascensia Diabetes Care's CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose meters have been successfully certified as meeting the recently developed DTS Cybersecurity Standard for Connected Diabetes Device Security (DTSec). Dr. David Klonoff (Diabetes Research Institute at Mills-Peninsula Health and Chair of the DTSec Steering Committee) revealed the news at this week's MEDSec: Security and Privacy for the Internet of Medical Things conference in San Jose, CA, demonstrating another important step forward in improving cybersecurity for people living with diabetes.
Evaluated and certified by the external security firm BrightSight, the world's largest independent security evaluator for high-criticality electronic products, the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters are the first devices of their kind to be certified to meet the rigorous DTSec cybersecurity standard. Ascensia has made recent updates to the software on these meters to improve cybersecurity and enable them to meet these requirements. DTSec has been pioneered by the Diabetes Technology Society (DTS) in order to raise confidence in the security of network-connected medical devices. It uses a framework that is based on IS0/IEC 15408 to evaluate the security of medical devices, software, and systems.